Regenxbio (RGNX) Capital Expenditures Growth (5y) (2020 - 2025)
Analysis
Regenxbio (RGNX) Capital Expenditures Growth (5y) (2020 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Regenxbio | 472.74 Mn | 367.22 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -47.62% |
| Sep 30, 2025 | -7.89% |
| Jun 30, 2025 | -24.23% |
| Mar 31, 2025 | -26.05% |
| Dec 31, 2024 | 0.91% |
| Sep 30, 2024 | 3.73% |
| Jun 30, 2024 | -17.39% |
| Mar 31, 2024 | -17.51% |
| Dec 31, 2023 | -25.45% |
| Sep 30, 2023 | -15.66% |
| Jun 30, 2023 | -0.73% |
| Mar 31, 2023 | 15.50% |
| Dec 31, 2022 | 21.09% |
| Sep 30, 2022 | 62.19% |
| Jun 30, 2022 | 40.62% |
| Mar 31, 2022 | 30.22% |
| Dec 31, 2021 | 26.93% |
| Sep 30, 2021 | 53.10% |
| Jun 30, 2021 | 79.36% |
| Mar 31, 2021 | 136.19% |